Treating cystic fibrosis
Additional therapy available to NHS.
A new triple therapy treatment will be available to cystic fibrosis patients on the NHS, following an agreement between the Scottish Government, NHS Scotland and the pharmaceutical company.
Kaftrio®, produced by Vertex Pharmaceuticals, is a medicine that tackles the underlying causes of the disease by helping the lungs work more effectively.
Health Secretary Jeane Freeman, yesterday said:
“Cystic fibrosis is an inherited condition, which tragically shortens lives and affects around 900 people in Scotland.
“I am therefore very pleased that a revised pricing agreement has been reached between NHS National Procurement and Vertex Pharmaceuticals, to ensure that Kaftrio®, can be made available for the treatment of cystic fibrosis through the NHS.
“This is a potentially transformational treatment for cystic fibrosis, and I am delighted that patients in Scotland will be among the first in Europe to benefit and lead longer, healthier lives.
“The deal, agreed ahead of a licence being granted by the European Medicines Agency, means that clinicians working in cystic fibrosis treatment centres, will be able to prescribe the medicine to patients whom they consider will benefit from their use as soon as the licence is granted, in the coming weeks.
“I hope that this news will be welcome to many people who live with cystic fibrosis, and also their families and friends.”
It is estimated that around 800 people with cystic fibrosis in Scotland should be suitable for treatment with the range of medicines that are now available.
The terms of the deal also mean that many patients with rare mutations, which fall outside of the scope of the European Medicines Agency’s current licensing considerations, will also be able to benefit from Kaftrio.
Latest News from
Ending the Throwaway Culture:-Five Principles for Tackling Single-use Items18/09/2020 16:38:00
This is the second, and final, Report of the Expert Panel for Environmental Charging and Other Measures.
Coronavirus (COVID-19): modelling the epidemic (issue no. 18)18/09/2020 15:05:00
Latest findings in modelling the COVID-19 epidemic in Scotland, both in terms of the spread of the disease through the population (epidemiological modelling) and of the demands it will place on the system, for example in terms of health care requirement.
The Impact of COVID-19 on Wellbeing in Scotland18/09/2020 13:05:00
Research into social impact of Covid-19.
Finance Ministers' "deep concern" over UK Internal Market Bill18/09/2020 10:05:00
Finance Ministers from Scotland, Wales and Northern Ireland have met to discuss a range of fiscal matters and voiced their collective concerns about the financial implications the UK Internal Market Bill will have on devolved governments.
Scottish Government support for Beirut18/09/2020 08:05:00
Three charities helping the people of Beirut recover from a disastrous explosion are to be supported by £300,000 from the Scottish Government.
Labour Market Statistics for young people (16 to 24 years): Scotland17/09/2020 15:05:00
New statistics from the Annual Population Survey show that 299,000 young people aged 16 to 24 years were in employment in Scotland in July 2019 to June 2020. The employment rate for young people was 53.2%, lower than a year ago (59.1%).
Impact of furlough17/09/2020 12:05:00
Extending the furlough scheme by eight months could save 61,000 jobs in Scotland, according to new research.
Economy contracts 19.4% in the second quarter of 202017/09/2020 08:05:00
The Chief Statistician has released statistics showing that the economy contracted by 19.4% during the second quarter of 2020, covering the period April to June.
Coronavirus (COVID-19) - extending the Coronavirus Job Retention Scheme: analysis16/09/2020 15:05:00
Paper exploring the costs and benefits of extending the Coronavirus Job Retention Scheme on a temporary basis. Such an extension could reduce unemployment in Scotland by 61,000 through the first half of 2021, at a cost of around £850 million.